InvestorsHub Logo
Followers 134
Posts 3758
Boards Moderated 0
Alias Born 01/28/2006

Re: farrell90 post# 335410

Wednesday, 12/02/2020 2:17:46 PM

Wednesday, December 02, 2020 2:17:46 PM

Post# of 403752
Next big news should be the announcements of human clinical Phase 2 human clinical trial protocols, sites ,dates. I look forward to Dr William Degrado's efforts and dreams to be fulfilled

CRO has been working hard for over a month:

Nov 2 PR

"Contract Research Organizations have been secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipates commencing the Brilacidin for COVID-19 clinical trial in 4Q2020."

July 7 PR

"Steps have begun with the Contract Development and Manufacturing Organization (CDMO) in preparation for upcoming manufacture of the drug product for COVID-19 clinical trial use, to be followed by interactions with relevant Health Authorities to obtain input and guidance on trial design.”

Nov 16 PR

"Sufficient Brilacidin intravenous (IV) drug product has been manufactured to complete this trial, and potentially future COVID-19 trials, providing the Company with added flexibility as it develops Brilacidin for the treatment of COVID-19."

Aug 26 news release
https://www.globenewswire.com/news-release/2020/08/26/2084130/0/en/Dr-William-F-DeGrado-a-Discoverer-of-Brilacidin-Joins-Innovation-Pharmaceuticals-as-Scientific-Advisor.html

" “I am excited to be involved again with Brilacidin, a unique biomimetic drug candidate that has been properly advanced clinically by Innovation across multiple indications,” said William F. DeGrado, PhD, Professor in the Department of Pharmaceutical Chemistry at University of California San Francisco (UCSF). “I look forward to collaborating with the Innovation team—most urgently, toward developing Brilacidin as a promising therapeutic to treat the novel coronavirus and possibly other viruses. Brilacidin already has exhibited intriguing anti-SARS-CoV-2 in vitro inhibitory efficacy at clinically-achievable concentrations based on Brilacidin pharmacokinetics seen in earlier clinical testing. The world is in dire need of new antiviral treatments and Brilacidin is well-positioned potentially to emerge as one.”

That is a lot of positive news in just a few months,isn't it?

GLTA Farrell